Metformin Manufacturing, Supply & Shortage History

From French Lilac to Factory Floor: A Brief Origin

Metformin's story begins with Galega officinalis, a plant used in medieval European folk medicine for symptoms we now recognize as diabetes. French chemist Emil Werner first synthesized dimethylbiguanide in 1922 [1]. The compound sat largely ignored for decades. Jean Sterne, a French physician, published the first clinical use data in 1957, and France approved metformin that same year under the brand name Glucophage.

The U.S. lagged behind by nearly four decades. Bristol-Myers Squibb (BMS) brought Glucophage to the FDA, which granted approval in December 1994, with commercial launch in March 1995 [2]. The delay stemmed partly from the 1977 withdrawal of phenformin, a chemically related biguanide pulled for fatal lactic acidosis. The FDA required BMS to demonstrate that metformin carried a far lower lactic acidosis risk. A pooled analysis of 347 trials later confirmed an incidence of only 6.3 per 100,000 patient-years [3].

BMS held patent exclusivity until 2002. That expiration opened the floodgates. By 2004, over a dozen generic manufacturers had received ANDA approvals, and wholesale pricing collapsed below $0.05 per tablet.

How Metformin Works: Mechanism in 200 Words

Metformin's primary action occurs in the liver. It suppresses hepatic glucose output by inhibiting mitochondrial complex I, which activates AMP-activated protein kinase (AMPK) [4]. This reduces gluconeogenesis by 25-36%, as measured by isotope tracer studies in patients with type 2 diabetes.

A second effect improves peripheral insulin sensitivity. Skeletal muscle glucose uptake increases, though the magnitude is smaller than the hepatic effect. Metformin also modifies the gut microbiome composition and increases GLP-1 secretion, a mechanism documented in a 2019 Nature Medicine study that found metformin shifted intestinal Akkermansia muciniphila abundance [5].

The drug does not cause hypoglycemia when used alone. It produces modest weight loss of 1-3 kg compared to sulfonylureas. UKPDS 34 (N=1,704) demonstrated a 32% reduction in any diabetes-related endpoint, a 42% reduction in diabetes-related death, and a 36% reduction in all-cause mortality compared to conventional dietary therapy in overweight patients with type 2 diabetes [1]. No other glucose-lowering drug had shown a mortality benefit at that time.

The Global API Supply Chain

Metformin hydrochloride API production is concentrated in South and East Asia. India accounts for roughly 60% of global output, with major facilities operated by Aarti Drugs, Wanbury, Amsal Chem, and Siddharth Carbochem. China contributes approximately 25%, with Shijiazhuang Polee Pharmaceutical and Wuhan Yuancheng among the largest producers [6].

European production exists but remains small. Merck KGaA operates a facility in Darmstadt, Germany. A handful of plants in Spain and Italy produce API primarily for the EU market. The raw material for metformin synthesis, dimethylamine and dicyandiamide, also originates predominantly from Chinese chemical manufacturers.

This geographic concentration creates vulnerability. When India's Maharashtra state locked down in March 2020, multiple metformin API plants halted or reduced output for weeks. The Indian government briefly restricted export of 26 APIs and formulations on March 3, 2020, though metformin was removed from that list within days after industry lobbying [7].

The typical supply chain runs five to seven steps: raw chemical synthesis in China, API manufacturing in India, finished dosage form production (often also in India), export to the U.S. or EU, packaging and labeling by the NDA/ANDA holder, distribution to wholesalers, and dispensing at pharmacies. Each step introduces potential delay points.

U.S. Generic Market Structure

More than 20 companies hold approved ANDAs for metformin immediate-release tablets in the United States. The extended-release (ER) market is similarly crowded. Major players include Teva Pharmaceutical, Amneal Pharmaceuticals, Aurobindo Pharma, Sun Pharmaceutical, Lupin, Zydus Lifesciences, and Granules India [8].

This level of competition keeps prices low. Too low, some argue. A 2021 analysis in the Journal of the American Medical Association found that 40% of generic drug markets with more than five approved manufacturers experienced at least one shortage between 2013 and 2019 [9]. The paradox: extreme price competition erodes profit margins to the point where manufacturers exit voluntarily or underinvest in quality systems, increasing the probability of production failures.

Metformin's wholesale acquisition cost for 500 mg IR tablets hovers between $0.02 and $0.06 per tablet. Brand-name Glucophage, still technically available, carries a wholesale price roughly 50 times higher, and its market share is negligible.

The Affordable Drug Manufacturing Act, introduced in Congress multiple times since 2018, proposed creating a government-backed manufacturer for drugs like metformin that face shortage risk precisely because they are too cheap for the market to reliably supply. The bill has not passed as of 2026.

The NDMA Crisis: 2020-2022

On February 3, 2020, an independent pharmacy Valisure petitioned the FDA after detecting N-nitrosodimethylamine (NDMA), a probable human carcinogen, in multiple metformin ER products at levels exceeding the acceptable daily intake limit of 96 nanograms [10]. The FDA had already been investigating NDMA contamination across drug classes following the 2018 valsartan recall.

The FDA's response unfolded in stages. Initial testing in March 2020 found NDMA in specific lots from specific manufacturers. The agency did not issue a blanket recall. Instead, it pursued a manufacturer-by-manufacturer approach:

• May 2020: Amneal Pharmaceuticals voluntarily recalled metformin ER 500 mg and 750 mg tablets (specific lots) after FDA testing confirmed NDMA above the acceptable intake limit [11].
• June 2020: Teva, Marksans, and Apotex issued recalls of their metformin ER products.
• July-August 2020: Lupin and Bayshore Pharmaceuticals followed.
• October 2020: Nostrum Laboratories recalled all lots of metformin ER 750 mg.

By late 2020, the FDA had tested over 100 batches from more than 30 manufacturers. Immediate-release formulations tested consistently clean. The contamination was confined to certain ER manufacturing processes, likely related to the specific polymer matrix or drying conditions used in sustained-release tablet production [12].

The recalls removed a significant portion of metformin ER supply from the U.S. market. The FDA placed metformin ER 500 mg and 750 mg on its Drug Shortage Database in 2020. The American Diabetes Association issued guidance recommending that patients remain on metformin IR if ER was unavailable, noting that the cardiovascular risk from stopping metformin outweighed the theoretical cancer risk from NDMA exposure at the detected levels [13].

Supply of ER formulations recovered through 2021 as manufacturers reformulated, implemented new NDMA testing protocols, and the FDA approved supplemental manufacturing changes. By early 2022, the FDA removed metformin ER from its shortage list.

Earlier Supply Disruptions

The 2020 NDMA event was not metformin's first encounter with shortage risk. In 2011-2012, a wave of FDA warning letters to Indian API manufacturers, including facilities supplying metformin intermediates, briefly constrained supply. The FDA's increased inspection activity following the 2008 heparin contamination crisis (which killed 81 people in the U.S.) led to import alerts and production stoppages at multiple facilities [14].

In 2017, Hurricane Maria devastated Puerto Rico, where several pharmaceutical plants produced finished dosage forms of metformin for the U.S. market. The disruption was brief for metformin specifically, because mainland facilities could absorb demand, but it exposed the general fragility of single-site dependencies in generic drug manufacturing.

The COVID-19 pandemic created a third category of disruption: demand surge. In March and April 2020, prescription fill volumes for metformin spiked 20-30% above baseline as patients panic-filled 90-day supplies [15]. This demand spike coincided with the NDMA recall removals, compounding the shortage.

Quality Control and Regulatory Oversight

The FDA inspects foreign manufacturing facilities that supply the U.S. market, but the inspection cadence is lower than for domestic sites. A 2019 Government Accountability Office (GAO) report found that the FDA inspected foreign drug manufacturing establishments once every 11 years on average, compared to once every 2.6 years for domestic facilities [16].

Dr. Janet Woodcock, then-Director of the FDA's Center for Drug Evaluation and Research, stated in 2019 congressional testimony: "We are dependent on a relatively small number of facilities overseas for the production of many critical medicines, and we do not have good visibility into the supply chain."

The FDA Reauthorization Act of 2017 (FDARA) expanded the agency's authority to require manufacturers to notify the FDA of anticipated supply disruptions at least six months in advance for drugs that could cause shortages. Metformin's 2020 NDMA shortage tested this system. Critics noted that the NDMA contamination was discovered by a third party, not by manufacturers or FDA inspectors, raising questions about the effectiveness of self-reporting mandates.

The Drug Quality and Security Act (DQSA) of 2013 established requirements for drug supply chain verification. Full implementation of its track-and-trace provisions, originally scheduled for 2023, has been extended. When fully operational, the system will require serialized tracking of every prescription drug package from manufacturer to pharmacy. Whether this prevents shortages is debatable; it addresses counterfeiting more directly than supply continuity [17].

Current Supply Status and Forward Outlook

As of May 2026, the FDA Drug Shortage Database lists no active shortages of metformin in any formulation. Both IR and ER tablets are widely available from multiple manufacturers. The NDMA testing infrastructure established during the 2020 crisis remains in place, with manufacturers conducting routine batch testing as a condition of continued marketing.

Several factors could affect future supply stability. India's Pollution Control Boards have increased enforcement against pharmaceutical waste discharge. At least three metformin API plants in Hyderabad faced temporary closure orders in 2023 and 2024 for effluent violations [18]. If environmental enforcement tightens further, production could shift to facilities with better waste treatment infrastructure, potentially causing transitional supply gaps.

The Biosecure Act, signed into law in late 2024, restricts U.S. government contracts with certain Chinese biotechnology companies but does not directly affect chemical API manufacturing. Proposed follow-on legislation, the DRUGS Act, would require API source-country labeling for all prescription drugs sold in the U.S. If passed, this transparency measure could accelerate the reshoring trend for critical medicines.

Global demand for metformin continues to grow. The drug's use in prediabetes prevention (based on the Diabetes Prevention Program trial showing 31% risk reduction vs. placebo over 2.8 years [19]), PCOS management, and investigational longevity applications (the TAME trial, Targeting Aging with Metformin, is enrolling 3,000 participants aged 65-79) increases consumption beyond its core type 2 diabetes indication [20].

Annual U.S. prescription volume exceeded 90 million in 2024 per IQVIA data. Worldwide production will need to scale accordingly. The WHO includes metformin on its Model List of Essential Medicines, and most countries maintain strategic stockpiles as part of their essential medicines programs [21].

Lessons From the Metformin Supply Chain

Three patterns recur across metformin's shortage history. First, geographic concentration of API manufacturing creates single points of failure that regulatory and natural disasters can exploit. Second, extreme generic price competition discourages the capital investment needed to maintain redundant, high-quality manufacturing capacity. Third, the FDA's surveillance systems detect contamination reactively rather than proactively; Valisure, a private pharmacy, identified the NDMA problem before the agency did.

The American Society of Health-System Pharmacists (ASHP) recommended in 2022 that health systems maintain 60-90 day buffer stocks of essential generic medications including metformin [22]. Whether individual institutions follow this guidance depends on their financial capacity to carry inventory costs for a drug that generates almost no margin.

For patients currently taking metformin, supply is stable. Clinicians prescribing metformin ER should verify that their patients' specific manufacturer has not been subject to any new quality actions by checking the FDA's MedWatch page. Patients experiencing difficulty obtaining metformin ER at a particular pharmacy should request the pharmacist check alternative NDC numbers from other approved manufacturers before assuming a shortage exists.